Global Influenza Vaccine Market: By Vaccine Type (Inactivated Influenza Vaccines, Live Attenuated Influenza Vaccines, Recombinant Influenza Vaccines, Cell-based Influenza Vaccines); By Strain Type (Trivalent, Quadrivalent); By Age Group (Paediatrics, Adults, Geriatrics); By Route of Administration (Intramuscular, Intradermal, Nasal Spray); By Distribution Channel (Hospitals & Clinics, Government Supply Programs, Retail Pharmacies, Others); Region Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025–2034.

The report offers the value (in USD Billion) for the above segments.

Region: Global | Format: Word, PPT, Excel | Report Status: Published

Global Influenza Vaccine Market Overview

The Global Influenza Vaccine Market was valued at USD  8.37 billion in 2024 and is projected to reach USD  18.02 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.97% during the forecast period 2025–2034

The surge in government-backed immunization efforts, growing influenza surveillance, and revamped pandemic preparedness strategies after COVID-19 are all momentum factors propelling the market notably. WHO Global Market Study on Seasonal Influenza Vaccines mentions that about 97 percent of influenza vaccines are consumed by high-income countries, indicating a strong correlation between public financing and uptake. The report also states that low-and-middle-income countries have limited coverage, although the WHO's Immunization Agenda 2030 initiatives are working to provide equitable access to vaccines globally, with increasing procurement of seasonal influenza doses by the public sector. This is the foundation of an evolving marketplace wherein the public health arm and manufacturers grow together to fulfil that demand-from-the-vulnerable populations, such as the elderly and those with chronic illnesses.

The annual influenza vaccination recommendations are relayed by the CDC through ACIP and have similar policies in Europe and Japan under guidance from ECDC and NIID respectively. It is also important to note that the CDC is maintaining support of the U.S. Flu Vaccine Effectiveness Network, providing further funding to support on-going effectiveness evaluations of currently- circulating vaccine strains and signalling, in keeping with the major public sector commitment to scientifically led deployment of vaccines. At a global level, the agency biannually updates for the Northern and Southern Hemispheres and influences vaccine composition adjustments soon with the Global Influenza Surveillance and Response System (GISRS). These quadrivalent update influences provide further hypothetical support to the market currently favoured over the trivalent vaccine by virtue of broader strain coverage and further integration structures in the national immunization schedule.

For seasonal influenza vaccination programs, WHO- strategic framework is functionality as a public health tool and infrastructure in preparation for a pandemic. For example, it cites that seasonal influenza manufacturing platforms could be swiftly repurposed during a pandemic that is caused by a new virus, for instance, H5N1 or H7N9. Meanwhile now, the 2021-2025 U.S. National Strategic Plan for Vaccines acknowledged seasonal flu vaccination as a primary strategy for respiratory health maintenance and reduced hospitalization burden during times characterized by co-circulation of respiratory viruses such as COVID-19. On the other hand, the ECDC is still assessing vaccine effectiveness across Europe and supports countries in evaluation of immunization program performance especially among target risk groups.

Public investment is also an important factor influencing vaccine innovation-for example, WHO and CDC have been major proponents next-generation natural flu vaccines including cell-based and recombinant vaccines to reduce dependency on egg-based manufacturing and improve efficacy against drifted strains. Although the dominant vaccines remain egg-based, public health authorities are increasingly associating themselves with diverse methods of production through partnerships or public-private consortia. In addition, intranasal formulations and mRNA combination vaccines against influenza and COVID-19 are under review by various national regulatory bodies with the backing of agencies such as the U.S. Biomedical Advanced Research and Development Authority (BARDA). Within a strong public sector involvement, the Global Influenza Vaccine Market is slated towards continuous expansion, as convergence in science, policy, and population health imperatives fuels this growth.

Market Drivers
  • Increasing Governmental Immunization Programs and Public Sector Spending on Preventive Care

Surge in public health spending for the influenza vaccination programs has become one of the main growth drivers for the global influenza vaccines market. The World Health Organization Global Market Study on Seasonal Influenza Vaccines 2024 states that almost 97% of global influzn vaccine doses are purchased by and administered in high-income countries, where the government heavily subsidizes the immunization campaigns. For example, systems such as the Vaccines for Children Program and Medicare in the United States, Canada, Australia, Germany, and Japan include influenza vaccines in the routine seasonal offerings. Government immunization programs ensure mass coverage of vulnerable populations such as the elderly, small children, and immunocompromised through coordination with the WHO and regional bodies such as the European Centre for Disease Prevention and Control. Usually, these are linked with influenza surveillance data collected through the WHO-GISRS, which enables monitoring of circulating strains and guiding the annual vaccine formulation. These institutional efforts instil greater public confidence, facilitate mobilization of the vaccines, and ensure sustained demand for vaccines through seasonal procurement cycles.

  • Global Pandemic Preparedness Strategies and Policy Focus on Respiratory Illnesses

Influenza vaccination has gained new strategic importance in pandemic preparedness. After the COVID-19 pandemic, governments recognized the necessity of local and global frameworks on pandemic preparedness. Among others, the U.S. Biomedical Advanced Research and Development Authority (BARDA) and Europe’s Horizon Europe health pillar have made investments in infrastructure for influenza vaccines, with heavy emphasis on scalability and rapid response related to emerging zoonotic strains such as H5N1. Because of the many manufacturers that would quickly turn to pandemic strain production on already established platforms, seasonal flu vaccination platforms have been singled out as critical preparedness for pandemics by the WHO. In addition, investments each year in flu surveillance, production capability, and outreach on flu vaccinations are included in national pandemic preparedness strategies, such as the U.S. National Strategic Plan for Vaccines (2021-2025). However, with this investment comes the recognition of seasonal intervention but also the critical line of defence against future pandemics. Continued public sector interest in the dual-use aspect of influenza vaccine infrastructure has, in turn, resulted in increasing budgets and integration into models for public health emergency response.

 

Market Opportunities
  • Next-Generation Technologies, Public R&D Support, and Equitable Vaccine Access Initiatives

The next generation of vaccine technology, the high advancement of which is coupled with the funding from and inter-agency collaboration by governments, is one of the important opportunities in the influenza vaccine market. At present, the WHO, CDC, and national controlling bodies are all promoting the switch from egg-based to recombinant, cell-based, and mRNA-based influenza vaccines, which are rather rewarding. Among the various advantages of these innovations, they include allocations from dedicated R&D budgets under pandemic preparedness schemes that are the sole characteristics of this type of research. In the U.S., for example, BARDA has given an award for the development of flexible platforms for influenza vaccines with timelines for rapid production and greater fidelity to specific antigenicity. WHO also champions partnerships such as Partnership for Influenza Vaccine Introduction (PIVI)-immunization agenda 2030 that contribute to increased access and immunization of low- and middle-income countries in terms of infrastructure, cold chain strengthening, and co-financing mechanisms with Gavi and UNICEF. Another promising area pertains to increased investments into universal influenza vaccines, giving hope that these projects will lead the way to broader-spectrum enhancers or vaccines undertaking that approach to developing a protection scheme underneath individual seasons against many strains of influenza. Most of these, being public-funded projects and/or in collaboration with institutes such as the NIH, will greatly reshape the market in the long run by reducing the need for annual reformulation of strains.

 

Market Restraining Factors
  • Supply Chain Inefficiencies, Strain Mismatch Risk, and Vaccine Hesitancy in Key Populations

Global influenza vaccine markets, despite public-sector involvement, have several challenges that hinder it in realizing its full potential. One of the biggest problems is the yearly risk of strain mismatch, whereby the circulating influenza virus differs significantly from the strains used in the vaccine. Often WHO and CDC stated that vaccine efficacy in some seasons was as low as 10-30%, damping public trust and program cost-effectiveness. Although improving strain surveillance and prediction has enhanced their accuracy, there remains an important constraint in terms of fixed time that elapses from strain selection to vaccine distribution. Apart from this, vaccine supply chains in LMICs face hurdles with cold chain logistics, procurement delays, and irregular distribution, compromising access to vaccines at the appointed time. This becomes even more acute during the seasons when outbreaks of several respiratory viruses (such as COVID-19 or RSV) overlap and stretch health infrastructure and crowd out flu vaccine delivery.

 

Segmentation Analysis

By Vaccine Type

The global influenza vaccination market is segmented by vaccine type into inactivated influenza vaccines (IIVs) and live attenuated influenza vaccines (LAIVs). Of these, IIVs dominate the market based on an established track record of safety, a track record of use in national immunization programs, and applicability to all age groups and risk profiles. The CDC says that most public health strategies adopt IIVs as the preferred option since they are comprised of non-replicating virus particles and thus pose little risk to immunocompromised patients. WHO guidelines for routine immunization also include the use of IIVs, especially for older adults, small children, and patients with chronic illnesses. IIVs have also formed a major component of national procurement and distribution schemes for high influenza vaccination coverage countries such as the United States, Canada, Germany, and Japan. LAIVs, however, will enjoy a relatively smaller share of the overall market due to low acceptance among older and immune-compromised people, although they are easily gaining ground on the paediatrics front due to administration without needles.

By Valency

By valency, the market is divided into Trivalent and Quadrivalent Influenza Vaccines. Quadrivalent vaccines are expected to hold the maximum share in the segment, primarily because of their larger coverage for strains which include two influenza A strains and two influenza B lineages. The current WHO biannual strain recommendation updates for both hemispheres entirely endorse quadrivalent formulations as the new global standard. After this, the public health authorities, such as the European Medicines Agency (EMA), CDC, and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), changed their guidance according to quadrivalent options realizing effectiveness during these seasonal outbreaks. National immunization programs between the U.S. and U.K. and Australia have also phased out trivalent offerings in Favor of a more widely acceptable quadrivalent vaccines. Most of them come from both egg-based and cell-culture manufacturing platforms, providing them a wide scope under public tenders and pharmacy networks.

By Route of Administration

Based on route of administration, the influenza vaccine market consists of two segments: Injectable and Intranasal. Injectable influenza vaccines account for the largest share because of their long history of proven safety and regular inclusion in worldwide immunization schedules, which makes this route popular in both public and private sectors for mass vaccination programs conducted by the governments. According to WHO's Global Influenza Vaccine Market Report for the year 2024, more than 90% of influenza doses dispensed worldwide are via the intramuscular route. It also accommodates the greatest age spectrum, ranging from old people to pregnant women and individuals with chronic medical conditions. Intranasal vaccines such as live attenuated forms have been very popular in using paediatric settings because of being easy to deliver and non-invasive; however, these face limited market penetration because of contraindications to some populations and higher expense. Nevertheless, this is likely to change with the ongoing government interests aimed at increasing vaccination compliance, especially in children and young persons-which in turn will most probably pave the way for gradual introduction of the intranasal route.

By Age Group

By age group, Paediatric, Adult, and Geriatrics comprise the target populations in market segmentation. The Adult segment presently monopolizes the market, following workplace vaccination policies, public awareness schemes, and the adverse effects of disease on working adults. With a growing tendency to include adults, national governments and public health agencies have incorporated them into the comprehensive respiratory virus mitigation strategy after COVID-19 revealed a more extensive adult immunization requirement. Nevertheless, the Geriatric segment is expected to grow at a rapid pace since it includes older populations at higher risk of complications related to influenza and the specific emphasis placed on elderly vaccination by WHO in the Immunization Agenda 2030. Furthermore, the growth in paediatric vaccination continues steadily, particularly in countries that have universal immunization programs such as the United States, U.K., and Australia, which recommends annual flu shots for children above six months. Global agencies like Gavi and UNICEF are also working with lower-income countries to improve access to vaccines for children, which will ensure continued growth in frontiers for diverse age groups.

Regional Snapshots

  • North America

North America tops the influenza vaccine market for its organized public immunization programs, CDC-backed wide-range surveillance systems, and extensive pharmaceutical infrastructure. Not mentioned, the United States occupies the largest share due to the yearly vaccination campaigns held under the CDC's National Influenza Vaccination Week and availability of quadrivalent and high-dose vaccines commercially. Both Public Health Agency of Canada and Canadian Immunization Research Network (CIRN) implement strategies on monitoring the efficacy of vaccines, as well as optimizing cold-chain distribution, focusing on seniors and indigenous populations. Government reimbursement schemes and active awareness by providers are still fostering market penetration in both countries.

  • Europe

At the European level, unified vaccine strategies are brought forth by the European Centre for Disease Prevention and Control (ECDC). Countries such as Germany, France, and the UK are highly seasonal vaccine-using countries. The European Medicines Agency allows centralized approvals and thus speeds the time to access novel formulations of influenza. Many countries have adopted universal vaccinations for the elderly, pregnant women, and people with chronic illnesses, for instance, the Netherlands and Italy. The EU Vaccines Strategy will channel funding public health initiatives for advanced research and development in mRNA flu vaccine candidates and innovative delivery platforms, including intranasal formulations.

  • Asia-Pacific

Influenza vaccine awareness has grown dramatically in the Asia-Pacific region in populous countries like China, India, and Japan. While Japan's Ministry of Health, Labour and Welfare (MHLW) stipulates the compulsory annual flu vaccination in health care and elderly facilities. China's National Immunization Program expands adult flu coverage in Tier-1 cities but made the NMPA streamline the vaccine approvals of imported and locally produced quadrivalent vaccines. ICMR and DBT are involved in promoting the broader uptake of vaccines against influenza in India among urban at-risk populations. These two countries have also included influenza immunization in their national immunization schedules and promoted local production in line with reducing import dependence.

  • Latin America

The world has so many things that can make it unsafety. Argentina, Brazil, and Mexico have many plans to vaccinate people across all ages against influenza by running government initiatives. The Brazilian Ministry of Health, for instance, runs a vibrant National Immunization Program (PNI) that includes free influenza vaccination for priority groups such as children, the elderly, and health workers. Mexico's efforts included integrating COFEPRIS and the national health insurance programs with calls for partnerships with the private sector to expand access to immunization. Local manufacturers, like Instituto Butantan in Brazil, are working on boosting production capacity for trivalent and quadrivalent influenza vaccines despite the logistical barriers posed by rural remoteness.

  • Middle East & Africa

influenza vaccine uptake in the Middle East and Africa is rather patchy but increasing slowly through the instrument of pandemic preparedness initiatives and the immunization campaigns by WHO. The Gulf Cooperation Council (GCC) member states are on board, particularly Saudi Arabia and the UAE, which have included seasonal influenza vaccination in the national health plans directed toward pilgrims, healthcare providers, and target high-risk populations. Extending seasonal surveillance and subsidized vaccine programs is the aim of the National Department of Health of South Africa, working with the National Institute for Communicable Diseases (NICD). However, limited and on-the-ground access to vaccines prevails across sub-Saharan Africa due to scarcity of funding, even though international partnerships are assisting a few pilot initiatives within regions.

 

List of Top Leading Companies
  • Sanofi
  • CSL Limited (Seqirus)
  • GlaxoSmithKline plc (GSK)
  • AstraZeneca plc
  • Moderna, Inc.
  • Pfizer Inc.
  • BioDiem Ltd
  • Novavax, Inc.
  • Daiichi Sankyo Company, Limited
  • Sinovac Biotech Ltd.
  • Hualan Biological Engineering Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Emergent BioSolutions Inc.
  • Medicago Inc. (a subsidiary of Mitsubishi Chemical)
  • Bharat Biotech International Limited

 

Key Industry Developments
  • 2024 (WHO & partners): The WHO held a meeting in February 2025 in support of strengthening seasonal influenza vaccination policies in countries. Among the actions discussed were flexible vaccination targets, a programmatic approach based on data, public-private partnerships, and national preparedness under the Global Influenza Strategy (2019-2030) and Immunization Agenda 2030.
  • 2025 (WHO): On 28 February 2025, WHO announced the recommendations for the viral composition of influenza vaccines for the 2025-26 northern hemisphere season to guide manufacturers in selecting strains based on GISRS data.
  • 2025 (EMA): In April 2025, EMA published its EU recommendations on the composition of the 2025-2026 influenza vaccine, recommending trivalent formulations for both egg-based and live-attenuated vaccines, with the exclusion of B/Yamagata due to lack of detection in recent surveillance.

 

Report Coverage

The report will cover the qualitative and quantitative data on the Global Influenza Vaccine Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Base Year

2024

Estimated Forecast Year

2025–34

Growth Rate

CAGR of 7.97% from 2025 to 2034

Unit

USD Billion

By Vaccine Type

 

  • Inactivated Influenza Vaccine (IIV)
  • Live Attenuated Influenza Vaccine (LAIV)
  • Recombinant Influenza Vaccine (RIV)

By Virus Type

 

  • Influenza A (H1N1)
  • Influenza A (H3N2)
  • Influenza B (Yamagata Lineage, Victoria Lineage)

By Formulation

 

  • Trivalent Vaccines
  • Quadrivalent Vaccines

By Route of Administration

 

  • Intramuscular (IM)
  • Intranasal
  • Intradermal

By Age Group

  • Paediatric (6 months–17 years)
  • Adults (18–64 years)
  • Geriatric (65 years and above)

By Distribution Channel         

  • Government Suppliers (e.g., public immunization programs)
  • Hospitals & Clinics
  • Pharmacies
  • Retail Drug Stores

By End User

  • Public Health Agencies
  • Hospitals
  • Clinics
  • Academic & Research Institutes

By Region

  • North America (U.S., Canada)
  • Europe (Germany, France, UK, Italy, Spain, Russia, Rest of Europe)
  • Asia-Pacific (China, India, Japan, ASEAN, Rest of Asia-Pacific)
  • Latin America (Brazil, Mexico, Rest of Latin America)
  • MEA (Saudi Arabia, South Africa, UAE, Rest Of MEA)

 

Global Influenza Vaccine Market Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Influenza Vaccine market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Influenza Vaccine. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Influenza Vaccine companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Influenza Vaccine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Influenza Vaccine Market Report is also available for below Regions and Country Please Ask for that

North America

  • U.S.
  • Canada

Europe

  • Switzerland
  • Belgium
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Sweden
  • Netherland
  • Turkey
  • Rest of Europe

Asia-Pacific

  • India
  • Australia
  • Philippines
  • Singapore
  • South Korea
  • Japan
  • China
  • Malaysia
  • Thailand
  • Indonesia
  • Rest Of APAC

Latin America

  • Mexico
  • Argentina
  • Peru
  • Colombia
  • Brazil
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest Of MEA

 

Points Covered in the Report
  • The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
  • The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 12 years data history and forecast.
  • The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
  • Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
  • The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

 

Key Reasons to Purchase
  • To gain insightful analyses of the Influenza Vaccine market and have comprehensive understanding of the global market and its commercial landscape.
  • Assess the production processes, major issues, and solutions to mitigate the development risk.
  • To understand the most affecting driving and restraining forces in the market and its impact in the global market.
  • Learn about the Influenza Vaccine market strategies that are being adopted by leading respective organizations.
  • To understand the future outlook and prospects for the Influenza Vaccine market. Besides the standard structure reports, we also provide custom research according to specific requirements.
 
Research Scope of Influenza Vaccine Market
  • Historic year: 2019- 2023
  • Base year: 2024
  • Forecast: 2025 to 2034
  • Representation of Market revenue in USD Million


Influenza Vaccine Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends:

  • PUBLISHED ON : June, 2025
  • BASE YEAR : 2023
  • STUDY PERIOD : 2020-2032
  • COMPANIES COVERED : 20
  • COUNTRIES COVERED : 25
  • NO OF PAGES : 380

Want to Review Complete Market Research Report

 $2800
 $4200
  $5600

Budget constraints? Get in touch with us for special pricing


Customize this Report

  • Buy specific segmentations (By Market Vertical, By Product Type) of this report
  • Buy specific region/country level reports
  • Request for Product Pricing Analysis, Market Dynamics, Recommendation & Conclusion
  • 20+ Company Profiles based on Project Requirement
  • Regulatory Analysis & Case Studies for Marketing Review
  • Competitive Landscape Analysis as per Client Requirement
  • Total Report Customization with Research Team Consultation
  • Why Choose Intellectual Market Insights?
  • Regional and Country Analysis
  • Parent/Child Market Analysis
  • SWOT analysis
  • Real-Time Market Attractiveness Index
  • Investment Pockets
  • Market Player Positioning
  • Competitive Heatmap
  • Product and penetration rate of segments. Policies and regulations analysis
  • Profiles of key companies operating in the market
  • Parent &Peer Market Analysis
  • Primary Survey Analysis & Transcripts
  • Premium insights from industry experts
  • Supply and Demand analysis
  • Financial Overview of Companies
  • Primary research (conducting interviews with CXO levels)
  • Marketing Survey
  • Market Trends & Opportunities
  • Market Growth Dynamics
  • Value/Supply Chain Analysis
  • Pre-&-Post Covid Market Scenario
  • Latest Technological Developments
  • Comprehensive Reports
  • 3-Rounds Quality Checks with Complete Assurance
  • Unlimited Post-Sales Support
  • Regular Report Updates
Didn't Get What you are looking for. Share your requirements here
Request for Customization